<DOC>
	<DOCNO>NCT00461929</DOCNO>
	<brief_summary>In order distinguish clonal instability drive imatinib CML actual change secondary clone induce imatinib would like investigate karyotype non-CML patient treat imatinib GIST patient .</brief_summary>
	<brief_title>Chromosome Abnormalities Chronic Myeloid Leukemia ( CML ) Imatinib . GIST Patients Imatinib</brief_title>
	<detailed_description>Chronic myeloid leukemia ( CML ) myeloproliferative disorder characterize presence Philadelphia ( Ph ) chromosome - ( 9:22 ) translocation result production BCR/ABL fusion protein Abl kinase activity . Imatinib mesylate ( Gleevec ) specifically target limit set protein tyrosine kinase - ABL , Arg ( Abl-related gene ) , c-Kit , platelet-derived growth factor receptor ( PDGF-R ) - oncogenic form , notably BCR/ABL Imatinib also potent inhibitor receptor-type c-Kit tyrosine kinase . Therefore imatinib examine therapeutic efficacy malignant gastro-intestinal stromal tumor ( GIST ) Recent article draw attention development new Ph-negative , cytogenetically unrelated clone therapy Ph-positive CML imatinib . Trisomy 8 monosomy 7 frequent defect , aberration also report . Some cytogenetic abnormality associate acute myeloid leukemia MDS .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Congenital Abnormalities</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Chromosome Aberrations</mesh_term>
	<mesh_term>Chromosome Disorders</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>GIST patient Imatinib 12 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2007</verification_date>
	<keyword>chronic myeloid leukemia</keyword>
	<keyword>gastrointestinal stromal cell tumor</keyword>
	<keyword>chromosome abnormality</keyword>
	<keyword>imatinib</keyword>
	<keyword>bone marrow aspiration</keyword>
</DOC>